Literature DB >> 7927225

The major metabolites of ursodeoxycholic acid in human urine are conjugated with N-acetylglucosamine.

H U Marschall1, W J Griffiths, U Götze, J Zhang, H Wietholtz, N Busch, J Sjövall, S Matern.   

Abstract

Ursodeoxycholic acid (750 mg/day) was administered orally to ten healthy subjects over a period of 10 days; 24 hr urine samples were collected the day before and on the last day of the study. Urinary bile acids were extracted, separated into groups of conjugates and analyzed by gas chromatography-mass spectrometry and fast atom bombardment mass spectrometry. Excretion of ursodeoxycholic acid rose from 70 to 2,915 micrograms/24 h. The highest increase was observed among N-acetylglucosamine conjugates, 90% of which constituted the previously unknown double conjugate of ursodeoxycholic acid with N-acetylglucosamine and glycine. Excretion of isoursodeoxycholic acid increased from 50 to 738 micrograms/24 h. This isomerization product of ursodeoxycholic acid was excreted almost exclusively as N-acetylglucosamine conjugate. In total, N-acetylglucosamine conjugates constituted 50% of urinary metabolites of ursodeoxycholic acid. In addition, metabolites of ursodeoxycholic acid hydroxylated at carbon atoms 1, 6, 22 and possibly 21 were observed. These compounds were also found as conjugates with N-acetylglucosamine. Their formation from ursodeoxycholic acid was definitely demonstrated by 13C-labeling after giving [24-13C]ursodeoxycholic acid to one of the healthy subjects and to a patient with extrahepatic cholestasis in whom hydroxylation of ursodeoxycholic acid at C-23 was also observed. The patient was also found to excrete the double conjugate of ursodeoxycholic acid with N-acetylglucosamine and taurine. The N-acetylglucosaminidation of ursodeoxycholic acid in vivo was shown to occur at C-7.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927225     DOI: 10.1002/hep.1840200412

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.

Authors:  Emmanouil Sinakos; Hanns-Ulrich Marschall; Kris V Kowdley; Alex Befeler; Jill Keach; Keith Lindor
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

2.  Fifty years with bile acids and steroids in health and disease.

Authors:  Jan Sjövall
Journal:  Lipids       Date:  2004-08       Impact factor: 1.880

Review 3.  Bile acids: analysis in biological fluids and tissues.

Authors:  William J Griffiths; Jan Sjövall
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

4.  Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase.

Authors:  Peter I Mackenzie; Anne Rogers; Joanna Treloar; Bo R Jorgensen; John O Miners; Robyn Meech
Journal:  J Biol Chem       Date:  2008-11-03       Impact factor: 5.157

5.  Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives.

Authors:  Ornella Baisini; Federica Benini; Felice Petraglia; Wilhelm Kuhnz; Santo Scalia; Hanns-Ulrich Marschall; Gabriele Brunetti; Horst-Dietmar Tauschel; Alberto Lanzini
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

Review 6.  Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades.

Authors:  Alan F Hofmann; Lee R Hagey
Journal:  J Lipid Res       Date:  2014-05-17       Impact factor: 5.922

7.  Identification of novel bile acids as biomarkers for the early diagnosis of Niemann-Pick C disease.

Authors:  Francesca Mazzacuva; Philippa Mills; Kevin Mills; Stephane Camuzeaux; Paul Gissen; Elena-Raluca Nicoli; Christopher Wassif; Danielle Te Vruchte; Forbes D Porter; Masamitsu Maekawa; Nariyasu Mano; Takashi Iida; Frances Platt; Peter T Clayton
Journal:  FEBS Lett       Date:  2016-05-27       Impact factor: 4.124

8.  Bile acid biosynthesis in Smith-Lemli-Opitz syndrome bypassing cholesterol: Potential importance of pathway intermediates.

Authors:  Jonas Abdel-Khalik; Thomas Hearn; Alison L Dickson; Peter J Crick; Eylan Yutuc; Karl Austin-Muttitt; Brian W Bigger; Andrew A Morris; Cedric H Shackleton; Peter T Clayton; Takashi Iida; Ria Sircar; Rajat Rohatgi; Hanns-Ulrich Marschall; Jan Sjövall; Ingemar Björkhem; Jonathan G L Mullins; William J Griffiths; Yuqin Wang
Journal:  J Steroid Biochem Mol Biol       Date:  2020-11-24       Impact factor: 4.292

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.